Patent US4937249A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4937249A Expired / Lapsed US ⏱️ 0.0 years remaining

Imide derivatives and their pharmaceutical use

Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1988-10-25
•
Granted: 1990-06-26
•
Expires: 2008-10-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A compound of the formula: ##STR1## or its acid addition salt, which is useful as a psychotic drug.

Inventors

  • 👤 Fujio Antoku
  • 👤 Mayumi Yoshigi
  • 👤 Ikutaro Saji
  • 👤 Kikuo Ishizumi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 16:31
CPC Classifications
C; C07; C07D; C07D413/00; C07D413/14; C07D417/00; C07D417/14

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 299 words
A compound of the formula: wherein A is a carbonyl group or a sulfonyl group; B is either one of the formulas: ##STR102## (in which R 1 and R 2 are each a hydrogen atom, or either one of them is a hydrogen atom and the other is a hydroxyl group, a C 1 -C 5 alkyl group or a C 2 -C 6 alkanoyloxy group, or R 1 and R 2 are combined together to represent an oxo group, E is a methylene group, an ethylene group or an oxygen atom and the full line accompanying a broken line ( ) indicates a single bond or a double bond), ##STR103## (in which F is a methylene group or an ethylene group and R 1 , R 2 and the full line accompanying a broken line ( ) are each as defined above), ##STR104## (in which R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each a hydrogen atom or a C 1 -C 5 alkyl group and R 1 , R 2 and the full line accompanying a broken line ( ) are each as defined above), or ##STR105## (in which R 9 and R 10 are each a C 1 -C 5 alkyl group) when A represents a carbonyl group, or B is a 1,2-phenylene group when A represents a sulfonyl group; W is a C 1 -C 6 alkylene group, a C 2 -C 6 alkenylene group, a C 2 -C 6 alkynylene group or a C 2 -C 6 alkylene group substituted with hydroxyl; and G is a hydrogen atom, a C 1 -C 5 alkyl group, a C 1 -C 5 alkoxy group, a halogen atom or a hydroxyl group, or its pharmaceutically acceptable salt.
Claim 2
Dependent Claim 299 words
A compound of the formula: wherein A is a carbonyl group or a sulfonyl group; B is either one of the formulas: ##STR102## (in which R 1 and R 2 are each a hydrogen atom, or either one of them is a hydrogen atom and the other is a hydroxyl group, a C 1 -C 5 alkyl group or a C 2 -C 6 alkanoyloxy group, or R 1 and R 2 are combined together to represent an oxo group, E is a methylene group, an ethylene group or an oxygen atom and the full line accompanying a broken line ( ) indicates a single bond or a double bond), ##STR103## (in which F is a methylene group or an ethylene group and R 1 , R 2 and the full line accompanying a broken line ( ) are each as defined above), ##STR104## (in which R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each a hydrogen atom or a C 1 -C 5 alkyl group and R 1 , R 2 and the full line accompanying a broken line ( ) are each as defined above), or ##STR105## (in which R 9 and R 10 are each a C 1 -C 5 alkyl group) when A represents a carbonyl group, or B is a 1,2-phenylene group when A represents a sulfonyl group; W is a C 1 -C 6 alkylene group, a C 2 -C 6 alkenylene group, a C 2 -C 6 alkynylene group or a C 2 -C 6 alkylene group substituted with hydroxyl; and G is a hydrogen atom, a C 1 -C 5 alkyl group, a C 1 -C 5 alkoxy group, a halogen atom or a hydroxyl group, or its pharmaceutically acceptable salt.
Claim 3
Dependent Claim 40 words
The compound according to claim 1, wherein A is a carbonyl group and B is a group of the formula: ##STR106## (in which R 1 and R 2 are each as defined in claim 1), or its pharmaceutically acceptable salt.
Claim 4
Dependent Claim 41 words
The compound according to claim 1, wherein A is a carbonyl group and B is a group of the formula: ##STR107## (in which F, R 1 and R 2 are each as defined in claim 1), or its pharmaceutically acceptable salt.
Claim 5
Dependent Claim 52 words
The compound according to claim 1, wherein A is a carbonyl group and B is a group of the formula: ##STR108## (in which R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each as defined in claim 1), or its pharmaceutically acceptable salt.
Claim 6
Dependent Claim 40 words
The compound according to claim 1, wherein A is a carbonyl group and B is a group of the formula: ##STR109## (in which R 9 and R 10 are each as defined in claim 1), or its pharmaceutically acceptable salt.
Claim 7
Dependent Claim 23 words
The compound according to claim 1, wherein A is a sulfonyl group and B is a 1,2-phenylene group, or its pharmaceutically acceptable salt.
Claim 8
Dependent Claim 71 words
The compound according to claim 1, wherein W is --(CH 2 ) 4 --, --CH 2 CH=CHCH 2 --, --CH 2 C=CCH 2 --, --CH 2 CH(OH)CH 2 CH 2 -- or --CH 2 CH 2 CH(OH)(CH 2 -- and G is a hydrogen atom, a C 1 -C 5 alkyl group, a C 1 -C 5 alkoxy group, a halogen atom or a hydroxyl group, or its pharmaceutically acceptable salt.
Claim 9
Dependent Claim 46 words
The compound according to claim 1, which is the one representable by the formula: ##STR110## wherein E' is a methylene group or an ethylene group and the full line accompanying a broken line ( ) is as defined in claim 1, or its pharmaceutically acceptable salt.
Claim 10
Dependent Claim 36 words
The compound according to claim 1, which is the one representable by the formula: ##STR111## wherein the full line accompanying a broken line ( ) is as defined in claim 1, or its pharmaceutically acceptable salt.
Claim 11
Dependent Claim 41 words
A pharmaceutical composition for treatment of psychosis which comprises an active ingredient a pharmaceutically effective amount of the compound (I) or its pharmaceutically acceptable acid addition salt according to claim 1, and at least one pharmaceutically acceptable inert carrier or diluent.
Claim 12
Dependent Claim 35 words
A method for treatment of psychosis which comprises administering a pharmaceutically effective amount of the compound (I) or its pharmaceutically acceptable acid addition salt according to claim 1 to a human being in need thereof.

References Cited (Backward Citations)

US4186203A Cited
US4399145A Cited
US4352811A Cited
US4355037A Cited
US4408054A Cited
US4408053A Cited
US4408054B1 Cited
US4411901A Cited
US4390544A Cited
US4524206A Cited
US4804663A Cited
US4812461A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-06-25 1993-12-25 1994-06-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-06-25 1997-12-25 1998-06-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-06-25 2001-12-25 2002-06-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag